Ustekinumab-aauzdrug info
1 ML ustekinumab-aauz 90 MG/ML Prefilled Syringe [Otulfi]
What it is used for
OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with:
moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy.
active psoriatic arthritis (PsA).
moderately to severely active Crohn's disease (CD).
moderately to severely active ulcerative colitis. Pediatric patients 6 years and older with:
moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy.
active psoriatic arthritis (PsA). 1.1 Plaque Psoriasis (PsO) OTULFI is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
1.2 Psoriatic
Arthritis (PsA) OTULFI is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis.
1.3 Crohn's
Disease (CD) OTULFI is indicated for the treatment of adult patients with moderately to severely active Crohn's disease.
1.4 Ulcerative
Colitis OTULFI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 16, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Ustekinumab-aauz, a human IgG1κ monoclonal antibody, is a human interleukin-12 and -23 antagonist. Using DNA recombinant technology, ustekinumab-aauz is produced in a Chinese hamster ovary (CHO) cell line. The manufacturing process contains steps for the clearance of viruses. Ustekinumab-aauz is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons. OTULFI (ustekinumab-aauz) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly brown-yellow solution with pH of 5.7- 6.3. OTULFI for Subcutaneous Use Available as 45 mg of ustekinumab-aauz in 0.5 mL and 90 mg of ustekinumab-aauz in 1 mL, supplied as a sterile solution in a single-dose prefilled syringe with a 29 gauge fixed ½ inch needle and as 45 mg of ustekinumab in 0.5 mL in a single-dose 3 mL Type I glass with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is not made with natural rubber (latex). Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab-aauz, histidine (0.512 mg), Polysorbate 80 (0.02 mg), sucrose (38 mg) and hydrochloric acid (to adjust pH). Each 1 mL prefilled syringe delivers 90 mg ustekinumab-aauz, histidine (1.024 mg), Polysorbate 80 (0.04 mg), sucrose (76 mg) and hydrochloric acid (to adjust pH). OTULFI for Intravenous Infusion Available as 130 mg of ustekinumab-aauz in 26 mL, supplied as a single-dose 30 mL Type I glass vial with a coated stopper. Each 26 mL vial delivers 130 mg ustekinumab-aauz, edetate disodium (0.47 mg), histidine (20 mg), L-histidine hydrochloride monohydrate (27 mg), methionine (10.4 mg), Polysorbate 80 (10.4 mg) and sucrose (2210 mg).
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 16, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance